Together, the three KCNT1 mutations investigated in this study account for approximately one fifth of patients identified to date, thus dosing information and any candidate drugs identified using the models will potentially benefit a significant proportion of people with KCNT1 epilepsy. The gene discussed is KCNT1; the disease is epilepsy.